Who is High-risk smoldering myeloma | Dr. S. Vincent Rajkumar

preview_player
Показать описание
Discussing how to treat MGUS (Monoclonal gammopathy of undetermined significance) and Smoldering Myeloma using an algorithm with Dr. S. Vincent Rajkumar. We covered MGUS and smoldering myeloma in great detail, following with how these patients should be monitored and if any of these patients should be treated. Dr. S. Vincent Rajkumar is a world-renowned physician who specializes in plasma cell disorders - Professor of Medicine at the Mayo Clinic Comprehensive Cancer Center.

#myeloma #multiplemyeloma #plasma #bonemarrow #carcinoma #oncology #oncbrothers #2023 #mayoclinic

Twitter:

/ oncbrothers
  1. OncBrothers: Practice-Changing Cancer Discussions
  2. practicechanging
  3. cancer
  4. oncology
  5. guidelines
  6. nccn
Рекомендации по теме
What is high-risk 0:04:47

What is high-risk smoldering myeloma? Criteria, risks, and ongoing research

What Causes Smoldering 0:02:37

What Causes Smoldering Myeloma and Who is at High Risk?

How is high-risk 0:04:04

How is high-risk smoldering multiple myeloma diagnosed?

The importance of 0:03:48

The importance of treating patients with smoldering myeloma at high risk of progression to myeloma

How to define 0:04:03

How to define high risk smoldering myeloma

Identifying high-risk smoldering 0:01:26

Identifying high-risk smoldering myeloma & minimizing treatment-related toxicity

Managing High-Risk Smoldering 0:04:05

Managing High-Risk Smoldering Myeloma

Who is High-risk 0:00:26

Who is High-risk smoldering myeloma | Dr. S. Vincent Rajkumar

Better understanding smoldering 0:01:04

Better understanding smoldering myeloma & improving the outcomes of patients with high-risk myel...

Treatments Available for 0:58:44

Treatments Available for High Risk Smoldering Myeloma Patients

Daratumumab in the 0:01:38

Daratumumab in the treatment of high-risk MGUS and low-risk smoldering myeloma

High Risk and 0:06:19

High Risk and Smoldering Multiple Myeloma

High-Risk Smoldering Multiple 0:04:03

High-Risk Smoldering Multiple Myeloma: Systemic Therapy

Genomic profiling of 0:02:20

Genomic profiling of smoldering myeloma identifies high- and low- risk patients

Investigating bispecific antibodies 0:01:23

Investigating bispecific antibodies in high-risk smoldering myeloma: the ImmunoPRISM platform study

Smoldering myeloma: Who 0:22:15

Smoldering myeloma: Who and when to treat?

Understanding the risk 0:01:11

Understanding the risk of progression of smoldering myeloma to provide more personalized therapies

How do the 0:04:40

How do the two approaches to treating high-risk smoldering multiple myeloma (HRSMM) patients differ?

When patients test 0:05:27

When patients test as having borderline high-risk smoldering myeloma, should they receive treatment?

Case 1: Patient 0:22:28

Case 1: Patient with high-risk smoldering myeloma

Evidence supporting lenalidomide 0:00:59

Evidence supporting lenalidomide for high-risk smoldering myeloma patients

Curative Strategy (GEM-CESAR) 0:02:30

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM)

Smoldering Myeloma: Who 0:19:19

Smoldering Myeloma: Who and when to treat?

Clinical and genomic 0:02:45

Clinical and genomic diagnosis of smoldering myeloma & identifying patients at risk of progressi...